Frangula Alnus Bark

The dosage of Frangula Alnus Bark must be carefully individualized based on the patient's response and the specific indication. Because it is a natural product, the concentration of active hydroxyanthracene glycosides can vary significantly between preparations.

• For Occasional Constipation: The standard adult dose is typically 20 mg to 30 mg of hydroxyanthracene derivatives (calculated as glucofrangulin A) per day. This is often achieved through 0.5 g to 2.0 g of the dried bark used in a decoction, or 200 mg to 500 mg of a standardized dry extract.
• As an Allergenic Extract: The dosage is highly specialized and determined by the allergist. It is usually administered in increasing concentrations (e.g., 1:100 w/v or 1:10 w/v) during skin testing or desensitization protocols.
• Nitrogen Binding: Dosage is determined by the specific clinical protocol and the patient's blood ammonia levels.

• Children 12 years and older: May use adult dosing under strict medical supervision, usually starting at the lowest possible range (10-15 mg of hydroxyanthracene derivatives).
• Children under 12 years: Frangula Alnus Bark is generally NOT recommended for children under the age of 12. Stimulant laxatives can cause severe abdominal cramping and rapid electrolyte shifts in younger children. Alternative treatments, such as osmotic laxatives or fiber supplements, are preferred.

Renal Impairment

Patients with impaired renal function should use Frangula Alnus Bark with extreme caution. The risk of electrolyte imbalance, particularly hypokalemia (low potassium), is significantly heightened in patients with chronic kidney disease (CKD). No specific GFR-based dosing exists, but frequency of use should be minimized.

Hepatic Impairment

While the primary action is local to the colon, the systemic absorption of aglycones requires hepatic conjugation. Patients with severe hepatic impairment (Child-Pugh Class C) should be monitored for potential accumulation of metabolites, though no formal dose reductions are established.

Elderly Patients

Geriatric patients are more susceptible to the dehydrating effects of stimulant laxatives. It is recommended to start at the absolute lowest effective dose (e.g., 10 mg glucofrangulins) and ensure adequate hydration (at least 6-8 glasses of water per day).

• Timing: It is best taken at bedtime. Because the transit time and microbial activation in the colon take approximately 6 to 12 hours, a bedtime dose typically results in a bowel movement the following morning.
• Administration: Tablets or capsules should be swallowed whole with a full glass of water (8 oz). Do not crush or chew standardized extracts unless directed. If using the raw bark for tea, boil the bark for 10-15 minutes and strain thoroughly.
• Duration: This medication should not be used for more than 7 to 10 consecutive days. Chronic use can lead to "lazy bowel syndrome" or dependency.
• Storage: Store in a cool, dry place away from direct sunlight. Anthraquinone glycosides can degrade if exposed to excessive moisture or heat.

If you miss a dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up. Taking an extra dose of a stimulant laxative can lead to severe abdominal pain and diarrhea.

Signs of overdose include severe abdominal cramping, profuse watery diarrhea, cold sweats, and extreme thirst (indicating dehydration). In severe cases, cardiac arrhythmias may occur due to potassium loss.

Emergency Measures:

1. 1Seek immediate medical attention or contact a Poison Control Center.
2. 2Rehydration is the priority, using oral rehydration salts or intravenous fluids in a clinical setting.
3. 3Electrolyte levels (sodium, potassium, chloride) must be monitored and corrected.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequent side effects associated with Frangula Alnus Bark are related to its primary mechanism of action in the gastrointestinal tract:

• Abdominal Cramping: Often described as a "griping" sensation, this occurs as the colon contracts more forcefully to move fecal matter.
• Diarrhea: If the dose is too high, stools may become liquid and frequent.
• Chromaturia: A harmless discoloration of the urine. Depending on the acidity (pH) of the urine, it may appear yellow-brown or reddish-pink. This is caused by the excretion of anthraquinone metabolites and will resolve once the medication is stopped.

• Nausea: Some patients may experience mild stomach upset shortly after ingestion.
• Vomiting: Less frequent than nausea, usually associated with higher doses.
• Mucus in Stool: Increased irritation of the colonic lining can lead to the passage of visible mucus.

• Dizziness: Usually secondary to mild dehydration or a vasovagal response to abdominal cramping.
• Allergic Dermatitis: Itching or rash, particularly in individuals with known sensitivities to the Rhamnaceae plant family.
• Proteinuria/Hematuria: In rare cases of high-dose use, irritation of the renal tubules may occur, leading to protein or blood in the urine.

> Warning: Stop taking Frangula Alnus Bark and call your doctor immediately if you experience any of the following serious symptoms:

• Severe Electrolyte Imbalance: Symptoms include muscle weakness, confusion, irregular heartbeat (arrhythmias), and extreme fatigue. This is most often caused by the loss of potassium (hypokalemia).
• Anaphylaxis: Although rare, as an allergenic extract, it can cause severe allergic reactions characterized by swelling of the face or throat, difficulty breathing, and a rapid drop in blood pressure.
• Severe Dehydration: Marked by sunken eyes, dry mouth, decreased urination, and fainting.
• Bloody Stools: While rare, significant irritation can lead to gastrointestinal bleeding, which requires immediate evaluation.

Prolonged or chronic use (longer than 2 weeks) of Frangula Alnus Bark can lead to several significant clinical issues:

1. 1Melanosis Coli: This is a benign, reversible pigmentation of the colonic mucosa. During a colonoscopy, the lining of the colon appears dark brown or black. It is caused by the accumulation of lipofuscin in macrophages within the lamina propria. It typically resolves 6-12 months after stopping the drug.
2. 2Cathartic Colon: A condition where the colon loses its natural muscle tone and ability to move stool independently. This can lead to chronic, severe constipation and a reliance on laxatives.
3. 3Pseudomembranous Colitis: Chronic irritation can occasionally mimic the symptoms of inflammatory bowel disease.
4. 4Renal Damage: Chronic use has been associated with an increased risk of kidney stones and permanent tubular damage due to chronic dehydration and electrolyte shifts.

There are currently no FDA Black Box Warnings specifically for Frangula Alnus Bark as an allergenic extract. However, healthcare providers emphasize that it should not be used in patients with undiagnosed abdominal pain, as it could mask symptoms of serious conditions like appendicitis.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Frangula Alnus Bark is intended for short-term use only. It is not a cure for chronic constipation and should not be used as a weight-loss aid. Misuse of stimulant laxatives for weight control can lead to permanent organ damage and life-threatening electrolyte disturbances.

No FDA black box warnings for Frangula Alnus Bark. However, clinical guidelines from the American Gastroenterological Association (AGA) strongly advise against the long-term use of anthraquinone-containing stimulants.

• Allergic Reactions / Anaphylaxis Risk: As a member of the Rhamnaceae family, individuals with known allergies to buckthorn, cascara, or certain pollens may experience cross-reactivity. If used as an allergenic extract, administration must occur in a facility equipped to handle anaphylaxis.
• Gastrointestinal Irritation: Frangula Alnus Bark should not be used if you have symptoms of appendicitis (nausea, vomiting, sudden stomach pain), as the increased peristalsis could lead to bowel perforation.
• Electrolyte Depletion: Patients on medications that also lower potassium (such as certain diuretics) are at high risk for cardiac complications. Monitoring of serum electrolytes is essential for any patient using this for more than 5 days.
• Laxative Dependency: Overuse can lead to a state where the bowels will not function without chemical stimulation.

For patients using Frangula Alnus Bark under medical supervision for more than a few days, the following may be required:

• Serum Electrolytes: Specifically potassium, sodium, and magnesium levels.
• Renal Function Tests: BUN and Creatinine to ensure dehydration is not affecting the kidneys.
• Urinalysis: To monitor for potential irritation-induced proteinuria.

Frangula Alnus Bark generally does not affect the ability to drive or operate machinery. However, if a patient experiences significant abdominal cramping or dizziness from dehydration, they should avoid these activities until symptoms resolve.

There is no direct chemical interaction between Frangula Alnus Bark and alcohol. However, alcohol is a diuretic and can exacerbate the dehydrating effects of the laxative. It is recommended to limit alcohol intake while using this product to prevent severe fluid loss.

If Frangula Alnus Bark has been used for an extended period, it should be tapered off slowly while simultaneously increasing dietary fiber (psyllium, methylcellulose) and fluid intake. Abruptly stopping after long-term use can lead to severe "rebound" constipation.

> Important: Discuss all your medical conditions with your healthcare provider before starting Frangula Alnus Bark.

• Other Stimulant Laxatives (e.g., Bisacodyl, Senna): Using Frangula Alnus Bark with other stimulants significantly increases the risk of severe cramping, dehydration, and electrolyte depletion. This combination provides no therapeutic benefit and carries high risk.

• Cardiac Glycosides (e.g., Digoxin): Frangula Alnus can cause potassium depletion (hypokalemia). Low potassium levels significantly increase the toxicity of Digoxin, potentially leading to life-threatening heart arrhythmias. Patients on Digoxin should avoid anthraquinone laxatives.
• Diuretics (e.g., Furosemide, Hydrochlorothiazide): These "water pills" also lower potassium. Using them with Frangula Alnus Bark creates a synergistic effect that can lead to profound hypokalemia.
• Corticosteroids (e.g., Prednisone): Systemic steroids can promote potassium loss. Combined use with Frangula Alnus increases the risk of electrolyte imbalance.

• Oral Anticoagulants (e.g., Warfarin): By speeding up intestinal transit time, Frangula Alnus Bark may reduce the absorption of Warfarin, potentially lowering its effectiveness and increasing the risk of blood clots. Additionally, chronic use can lead to Vitamin K malabsorption, which would conversely increase the effect of Warfarin. Close INR monitoring is required.
• Antiarrhythmics (e.g., Sotalol, Amiodarone): The effectiveness of these drugs is highly dependent on stable potassium levels. Electrolyte shifts caused by Frangula Alnus can trigger arrhythmias in these patients.

• Dairy Products: While not a direct interaction, consuming large amounts of dairy while taking a laxative can sometimes worsen cramping in lactose-intolerant individuals.
• Licorice Root (Natural): Large amounts of natural licorice can also lower potassium, compounding the risk of hypokalemia.

• Horsetail (Equisetum): This herb has diuretic properties and can contribute to potassium loss.
• Aloe Vera (Oral Juice): Contains similar anthraquinones; combining these increases the risk of toxicity.
• St. John's Wort: While no direct PK interaction is known, the potential for GI upset may be additive.

• Urine Tests: The metabolites of Frangula Alnus can cause false-positive results in urine tests for urobilinogen or certain estrogens when using colorimetric methods.
• Phenolsulfonphthalein (PSP) Excretion Test: The presence of anthraquinones in the urine can interfere with the color readings of this kidney function test.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Frangula Alnus Bark must NEVER be used in the following circumstances:

• Bowel Obstruction or Ileus: If the intestines are physically blocked, stimulating peristalsis can lead to a catastrophic bowel rupture (perforation).
• Acute Inflammatory Bowel Diseases: This includes Crohn's disease and Ulcerative Colitis. The irritating nature of the anthraquinones can trigger a severe flare-up or lead to toxic megacolon.
• Appendicitis: Stimulating the bowel during active appendicitis increases the risk of the appendix bursting.
• Undiagnosed Abdominal Pain: Using a laxative when the cause of pain is unknown can mask symptoms of surgical emergencies (e.g., ectopic pregnancy, ruptured cyst).
• Severe Dehydration: Patients already in a fluid-depleted state should not take medications that cause further water loss.
• Children under 12: Due to the high risk of rapid electrolyte shifts.

• Pregnancy and Lactation: Use should be avoided unless specifically directed by a physician, as anthraquinones can stimulate uterine contractions or pass into breast milk.
• Hemorrhoids or Anal Fissures: While sometimes used to soften stool, the increased frequency of bowel movements and the irritating nature of the metabolites can sometimes worsen local inflammation.
• Chronic Kidney Disease: Requires extreme caution due to the risk of potassium imbalance.

Patients who have had an allergic reaction to Cascara Sagrada, Senna, or Rhubarb (Rheum) are likely to be cross-sensitive to Frangula Alnus Bark, as these plants all contain similar hydroxyanthracene glycosides.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Frangula Alnus Bark.

FDA Pregnancy Category: Not Officially Assigned (Typically treated as Category C/D).

Frangula Alnus Bark is not recommended during pregnancy. There are two primary concerns:

1. 1Uterine Stimulation: Anthraquinones may theoretically stimulate uterine contractions, potentially increasing the risk of premature labor or miscarriage, especially in the first and third trimesters.
2. 2Genotoxicity: Some metabolites (like emodin) have shown genotoxic potential in in vitro studies, although human data is lacking. Most obstetricians recommend osmotic laxatives (like polyethylene glycol) or stool softeners as safer alternatives.

Small amounts of the active metabolites (aglycones) can pass into breast milk. While the concentration is usually low, it can cause increased bowel activity or diarrhea in the nursing infant. Therefore, use is generally discouraged during breastfeeding. If use is necessary, the infant should be closely monitored for loose stools or signs of colic.

Safety and efficacy have not been established in children under 12 years of age. Pediatric patients are at a much higher risk for "paradoxical" reactions and severe dehydration. In children, constipation is often behavioral or related to diet; therefore, stimulant laxatives are considered a last resort and should only be used under the guidance of a pediatric gastroenterologist.

Patients over the age of 65 are the most frequent users of laxatives but also the most vulnerable to their side effects.

• Dehydration Risk: Reduced thirst sensation in the elderly makes them prone to severe dehydration from stimulant-induced diarrhea.
• Polypharmacy: Elderly patients are often on diuretics or Digoxin, making the interaction with Frangula Alnus Bark particularly dangerous.
• Dosing: Should always start at 50% of the standard adult dose.

In patients with a GFR < 30 mL/min, the kidneys cannot effectively manage the electrolyte shifts caused by Frangula Alnus. The risk of hypernatremia (high sodium) or hypokalemia (low potassium) is significant. Use is generally avoided in patients on dialysis unless specifically managed by a renal specialist.

No specific dose adjustments are required for mild to moderate hepatic impairment. However, in patients with end-stage liver disease or hepatic encephalopathy, the use of Frangula Alnus as a Nitrogen Binding Agent must be balanced against the risk of dehydration, which can actually worsen encephalopathy.

> Important: Special populations require individualized medical assessment.

Frangula Alnus Bark operates as a prodrug stimulant laxative. The primary constituents are glucofrangulins A and B (anthraquinone diglycosides). These molecules are too large and polar to be absorbed in the small intestine. Upon reaching the colon, the enzyme rhamnosidase (produced by gut bacteria) removes the rhamnose sugar, and beta-glucosidase removes the glucose molecule.

This releases the active aglycone, frangula-emodin. This compound acts directly on the Auerbach’s plexus (myenteric plexus) to increase colonic motility. Simultaneously, it inhibits the Na+/K+-ATPase pump in the basolateral membrane of the enterocytes. This leads to an accumulation of electrolytes and water in the intestinal lumen, increasing the volume and pressure within the colon, which triggers the defecation reflex.

• Onset of Action: 6 to 12 hours (the time required for transit to the colon and bacterial activation).
• Duration of Effect: 2 to 4 hours after the onset of the first bowel movement.
• Tolerance: With repeated use, the colon may become desensitized to the irritating effects of the anthraquinones, requiring higher doses to achieve the same effect.

| Parameter | Value |

|---|---|

| Bioavailability | < 5% (as glycosides) |

| Protein Binding | 80-90% (for emodin) |

| Half-life | 6-10 hours (metabolites) |

| Tmax | 8-12 hours (for effect) |

| Metabolism | Hepatic (Glucuronidation/Sulfation) |

| Excretion | Fecal (major), Renal (minor) |

• Molecular Formula (Glucofrangulin A): C27H30O14
• Molecular Weight: 578.5 g/mol
• Solubility: Glycosides are water-soluble; aglycones are lipid-soluble.
• Structure: Consists of an anthracene ring system with hydroxyl and methyl groups, attached to sugar moieties.

Frangula Alnus Bark is classified as a Stimulant Laxative within the broader category of Anthranoid-containing botanicals. In specialized settings, it is categorized as a Non-Standardized Plant Allergenic Extract [EPC].